Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States?
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of Teva’s Copaxone 40 mg three-times-weekly (3TW) and Biogen Idec’s Plegridy for the treatment of relapsing forms of multiple sclerosis (MS). Along with trial, adoption, and uptake of these disease-modifying therapies (DMTs), the report assesses U.S. neurologists’ perceptions on the uniqueness and drivers of preferential prescribing of Copaxone 40 mg 3TW and Plegridy compared with other marketed DMTs. With a potential launch of generic glatiramer acetate (GA) occurring in the next year, neurologists are also surveyed about its likely effect on MS prescribing decisions and the competitive landscape.
